New Research Coverage Highlights PROS, BioLife Solutions, Home BancShares, Revance Therapeutics, HomeStreet, and Ennis — Consolidated Revenues, Company Growth, and Expectations for 2018

New Research Coverage Highlights PROS, BioLife Solutions, Home BancShares, Revance Therapeutics, HomeStreet, and Ennis — Consolidated Revenues, Company Growth, and Expectations for 2018

NEW YORK, Feb. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PROS Holdings, Inc. (NYSE:PRO), BioLife Solutions, Inc. (NASDAQ:BLFS), Home BancShares, Inc. (NASDAQ:HOMB), Revance Therapeutics, Inc. (NASDAQ:RVNC), HomeStreet, Inc. (NASDAQ:HMST), and Ennis, Inc. (NYSE:EBF), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

PRO DOWNLOAD: http://Fundamental-Markets.com/register/?so=PRO
BLFS DOWNLOAD: http://Fundamental-Markets.com/register/?so=BLFS
HOMB DOWNLOAD: http://Fundamental-Markets.com/register/?so=HOMB
RVNC DOWNLOAD: http://Fundamental-Markets.com/register/?so=RVNC
HMST DOWNLOAD: http://Fundamental-Markets.com/register/?so=HMST
EBF DOWNLOAD: http://Fundamental-Markets.com/register/?so=EBF

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine PROS Holdings, Inc. (NYSE:PRO), BioLife Solutions, Inc. (NASDAQ:BLFS), Home BancShares, Inc. (NASDAQ:HOMB), Revance Therapeutics, Inc. (NASDAQ:RVNC), HomeStreet, Inc. (NASDAQ:HMST), and Ennis, Inc. (NYSE:EBF) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 26th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

PROS HOLDINGS, INC. (PRO) REPORT OVERVIEW

PROS's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, PROS reported revenue of $46.34MM vs $39.93MM (up 16.07%) and basic earnings per share -$0.52 vs -$0.59. For the twelve months ended December 31st, 2017 vs December 31st, 2016, PROS reported revenue of $168.82MM vs $153.28MM (up 10.14%) and basic earnings per share -$2.46 vs -$2.47. PROS is expected to report earnings on May 1st, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.34. The estimated EPS forecast for the next fiscal year is -$1.20 and is expected to report on February 5th, 2019.

To read the full PROS Holdings, Inc. (PRO) report, download it here: http://Fundamental-Markets.com/register/?so=PRO

-----------------------------------------

BIOLIFE SOLUTIONS, INC. (BLFS) REPORT OVERVIEW

BioLife Solutions' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, BioLife Solutions reported revenue of $2.96MM vs $2.14MM (up 38.79%) and basic earnings per share -$0.03 vs -$0.08. For the twelve months ended December 31st, 2016 vs December 31st, 2015, BioLife Solutions reported revenue of $8.23MM vs $6.45MM (up 27.57%) and basic earnings per share -$0.54 vs -$0.35. BioLife Solutions is expected to report earnings on March 8th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.04. The estimated EPS forecast for the next fiscal year is -$0.10 and is expected to report on March 8th, 2018.

To read the full BioLife Solutions, Inc. (BLFS) report, download it here: http://Fundamental-Markets.com/register/?so=BLFS

-----------------------------------------

HOME BANCSHARES, INC. (HOMB) REPORT OVERVIEW

Home BancShares' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Home BancShares reported interest income of $158.98MM vs $111.39MM (up 42.73%) and basic earnings per share $0.13 vs $0.34 (down 61.76%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Home BancShares reported interest income of $520.25MM vs $436.54MM (up 19.18%) and basic earnings per share $0.90 vs $1.26 (down 28.57%). Home BancShares is expected to report earnings on April 19th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $1.89 and is expected to report on January 17th, 2019.

To read the full Home BancShares, Inc. (HOMB) report, download it here: http://Fundamental-Markets.com/register/?so=HOMB

-----------------------------------------

REVANCE THERAPEUTICS, INC. (RVNC) REPORT OVERVIEW

Revance Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Revance Therapeutics reported revenue of $0.08MM vs $0.08MM (unchanged) and basic earnings per share -$1.01 vs -$0.64. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Revance Therapeutics reported revenue of $0.30MM vs $0.30MM (unchanged) and basic earnings per share -$3.18 vs -$3.02. Revance Therapeutics is expected to report earnings on February 28th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.95. The estimated EPS forecast for the next fiscal year is -$3.46 and is expected to report on February 28th, 2018.

To read the full Revance Therapeutics, Inc. (RVNC) report, download it here: http://Fundamental-Markets.com/register/?so=RVNC

-----------------------------------------

HOMESTREET, INC. (HMST) REPORT OVERVIEW

HomeStreet's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, HomeStreet reported interest income of $63.69MM vs $56.86MM (up 12.00%) and basic earnings per share $1.30 vs $0.09 (up 1,344.44%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, HomeStreet reported interest income of $237.68MM vs $209.54MM (up 13.43%) and basic earnings per share $2.57 vs $2.36 (up 8.90%). HomeStreet is expected to report earnings on April 23rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $2.66 and is expected to report on January 28th, 2019.

To read the full HomeStreet, Inc. (HMST) report, download it here: http://Fundamental-Markets.com/register/?so=HMST

-----------------------------------------

ENNIS, INC. (EBF) REPORT OVERVIEW

Ennis' Recent Financial Performance

For the three months ended November 30th, 2017 vs November 30th, 2016, Ennis reported revenue of $93.61MM vs $88.66MM (up 5.58%) and basic earnings per share $0.33 vs $0.22 (up 50.00%). For the twelve months ended February 28th, 2017 vs February 29th, 2016, Ennis reported revenue of $356.89MM vs $385.95MM (down 7.53%) and basic earnings per share $0.07 vs $1.39 (down 94.96%). Ennis is expected to report earnings on April 24th, 2018. The report will be for the fiscal period ending February 28th, 2018.

To read the full Ennis, Inc. (EBF) report, download it here: http://Fundamental-Markets.com/register/?so=EBF

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.